S Mehta Neesurg, Emami-Naeini Parisa
Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, CA, USA.
J Ophthalmic Vis Res. 2022 Apr 29;17(2):276-289. doi: 10.18502/jovr.v17i2.10804. eCollection 2022 Apr-Jun.
Uveitis is one of the most common causes of vision loss and blindness worldwide. Local and/or systemic immunosuppression is often required to treat ocular inflammation in noninfectious uveitis. An understanding of safety and efficacy of these medications is required to individualize treatment to each patient to ensure compliance and achieve the best outcome. In this article, we reviewed the effectiveness of systemic biologic response modifiers and local treatments commonly used in the management of patients with noninfectious uveitis.
葡萄膜炎是全球范围内导致视力丧失和失明的最常见原因之一。在非感染性葡萄膜炎中,治疗眼部炎症通常需要局部和/或全身免疫抑制。为了针对每位患者进行个体化治疗以确保依从性并取得最佳疗效,需要了解这些药物的安全性和有效性。在本文中,我们回顾了全身生物反应调节剂和常用于治疗非感染性葡萄膜炎患者的局部治疗方法的有效性。